The　development　of　combination　of　two　or　more　therapies　to　fight　against　cancer　together　has　been　important　research　in　oncology.　Here　we　rationally　designed　a　novel　nanodrug　which　can　incorporate　active　targeting,　antibody　therapy,　drug　therapy　and　photothermal　therapy　within　one　single　platform　to　fight　against　Her2-positive　breast　cancer.　To　this　end,　a　layer　of　mesoporous　SiO2　was　encapsulated　onto　the　gold　nanorods　followed　by　covalent　association　of　breast　cancer　drug　TDM1　to　the　silica　shell.　TDM1　is　an　antibody　drug　conjugate　consisting　of　engineered　antibody　trastuzumab　and　anti-miotic　agent　emtansine.　Drug　therapy　followed　by　photothermal　therapy　using　NIR　laser　(793nm)　specifically　ablated　Her2-positive　breast　cancer　cells　with　enhanced　efficiency.　In　addition,　the　engineered　nanodrug　has　amplified　photoacoustic　performance　allowing　sensitive　detection　of　Her2-positive　cancer　cells.